| 前收市價 | 24.33 |
| 開市 | 24.48 |
| 買盤 | 24.82 x 400 |
| 賣出價 | 24.88 x 100 |
| 今日波幅 | 24.32 - 24.99 |
| 52 週波幅 | 12.75 - 44.32 |
| 成交量 | |
| 平均成交量 | 1,700,660 |
| 市值 | 4.656B |
| Beta 值 (5 年，每月) | 1.03 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.95 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 49.75 |
ZacksWill BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksBayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
Investor's Business DailyBridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.
